STOCK TITAN
  1. Home
  2. News
  3. SRPT

Sarepta Therapeutics Inc - SRPT STOCK NEWS

Welcome to our dedicated news page for Sarepta Therapeutics (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sarepta Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sarepta Therapeutics's position in the market.

News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. granted equity awards to 8 new employees under its 2024 Employment Commencement Incentive Plan, totaling 5,100 stock options and 9,335 restricted stock units. The options have an exercise price of $129.46 per share, with vesting schedules over four years. This move aims to incentivize and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
News
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) will participate in fireside chats at two upcoming investor conferences in March 2024. The presentations will be webcast live and archived on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
conferences
-
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. granted equity awards to 5 new employees as a material inducement to employment, including options to purchase 0 shares of common stock and 6,300 restricted stock units. The options have an exercise price of $127.90 per share, vesting over four years, while the RSUs vest yearly, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
News
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) launches Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year, offering up to $5,000 in scholarships to individuals living with Duchenne muscular dystrophy and their siblings. Applications accepted until May 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
none
-
News
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Rhea-AI Summary
Sarepta Therapeutics (SRPT) reports strong financial results for Q4 2023 with net product revenues totaling $365.1 million, a 55% increase YoY. Full-year 2023 net product revenues reached $1.1 billion, a 36% increase. The company achieved GAAP profitability in Q4 2023 after non-GAAP profitability in Q3 2023. Positive developments include FDA acceptance of an efficacy supplement for ELEVIDYS and positive data from the MOMENTUM study on SRP-5051.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
earnings
-
News
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) will announce its Q4 and full-year 2023 financial results on Feb. 28, 2024. A conference call will follow to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
earnings
News
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Rhea-AI Summary
Sarepta Therapeutics (NASDAQ: SRPT) receives Priority Review from the FDA for ELEVIDYS, a treatment for Duchenne muscular dystrophy, aiming to broaden the approved indication and convert accelerated approval to traditional.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
clinical trial
-
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards to 14 individuals as a material inducement to employment. The employees received options to purchase 6,925 shares of Sarepta's common stock and 4,950 restricted stock units. The options have an exercise price of $118.99 per share, with vesting schedules over a four-year period. The RSUs will also vest yearly over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
-
News
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced positive data from Part B of the MOMENTUM study for SRP-5051, a treatment for Duchenne muscular dystrophy. The data showed substantial increases in dystrophin expression and exon skipping, indicating a favorable benefit-risk profile for SRP-5051.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
News
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Rhea-AI Summary
Sarepta Therapeutics (SRPT) has announced the initiation of screening in Study SRP-9003-301, a Phase 3, multi-national, open-label study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4). The study will enroll 15 participants aged 4 and older and uses commercially representative process SRP-9003 material. Early results from the SRP-9003 clinical development program have shown significant protein expression and functional benefits, including slowing disease progression, improving mobility, and enhancing the quality of life for individuals with LGMD2E.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
acquisition clinical trial
Stock SRPT logo
Sarepta Therapeutics Inc

Nasdaq:SRPT

SRPT Rankings

#748 Ranked by Market Cap
#2404 Ranked by Stock Gains
N/A Ranked by Dividends

SRPT Stock Data

11.53B
89.61M
4.3%
87.88%
4.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SRPT

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.